StockMacro
Company, fund or insider

Help

Menu

Pacira BioSciences

$36.48 +50% in 6 monthsMarket cap $1.5B

PCRX on XNAS, Health Care, Pacira BioSciences, Inc., job postings

Measures activity, not value. Not investment advice.

Annual profit up 76% to $37.7M, but latest quarter revenue fell 1.6% while shares gained 53% in a year.

  • BadReceived 1 delisting notice in the last 90 days
  • WatchShort interest 8.4%, down 21% on the report two weeks earlier

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Industry
Pharmaceutical preparations (Health Care)
Employees
829
Website
pacira.com
Listed
Nasdaq, US
Last results
4 Aug 2026
Next results
expected around 7 Jan 2027 (an estimate: a year ago it reported on 8 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $176.7M, net income $28.5M.
Quarter to 31 Dec 2021: revenue –, net income -$5.1MQuarter to 31 Mar 2022: revenue $158.0M, net income $6.8MQuarter to 31 Mar 2022: revenue $158.0M, net income $6.8MQuarter to 30 Jun 2022: revenue $169.4M, net income $19.9MQuarter to 30 Jun 2022: revenue $169.4M, net income $19.9MQuarter to 30 Sep 2022: revenue $167.5M, net income -$693KQuarter to 30 Sep 2022: revenue $167.5M, net income -$693KQuarter to 31 Dec 2022: revenue $172.0M, net income -$10.1MQuarter to 31 Dec 2022: revenue $172.0M, net income -$10.1MQuarter to 31 Mar 2023: revenue $160.3M, net income -$19.5MQuarter to 31 Mar 2023: revenue $160.3M, net income -$19.5MQuarter to 30 Jun 2023: revenue $169.5M, net income $25.8MQuarter to 30 Jun 2023: revenue $169.5M, net income $25.8MQuarter to 30 Sep 2023: revenue $163.9M, net income $10.9MQuarter to 30 Sep 2023: revenue $163.9M, net income $10.9MQuarter to 31 Dec 2023: revenue $181.2M, net income $24.9MQuarter to 31 Dec 2023: revenue $181.2M, net income $24.9MQuarter to 31 Mar 2024: revenue $167.1M, net income $9.0MQuarter to 31 Mar 2024: revenue $167.1M, net income $9.0MQuarter to 30 Jun 2024: revenue $178.0M, net income $18.9MQuarter to 30 Jun 2024: revenue $178.0M, net income $18.9MQuarter to 30 Sep 2024: revenue $168.6M, net income -$143.5MQuarter to 30 Sep 2024: revenue $168.6M, net income -$143.5MQuarter to 31 Dec 2024: revenue $187.3M, net income $16.0MQuarter to 31 Dec 2024: revenue $187.3M, net income $16.0MQuarter to 31 Mar 2025: revenue $168.9M, net income $4.8MQuarter to 31 Mar 2025: revenue $168.9M, net income $4.8MQuarter to 30 Jun 2025: revenue $181.1M, net income -$4.8MQuarter to 30 Jun 2025: revenue $181.1M, net income -$4.8MQuarter to 30 Sep 2025: revenue $179.5M, net income $5.4MQuarter to 30 Sep 2025: revenue $179.5M, net income $5.4MQuarter to 31 Dec 2025: revenue $196.9M, net income $1.6MQuarter to 31 Dec 2025: revenue $196.9M, net income $1.6MQuarter to 31 Mar 2026: revenue $177.4M, net income $2.9MQuarter to 31 Mar 2026: revenue $177.4M, net income $2.9MQuarter to 30 Jun 2026: revenue $192.4M, net income $4.7MQuarter to 30 Jun 2026: revenue $192.4M, net income $4.7MQuarter to 30 Sep 2026: revenue $176.7M, net income $28.5MQuarter to 30 Sep 2026: revenue $176.7M, net income $28.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $196.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$176.7M$28.5M
30 Jun 2026$192.4M$4.7M
31 Mar 2026$177.4M$2.9M
31 Dec 2025$196.9M$1.6M
30 Sep 2025$179.5M$5.4M
30 Jun 2025$181.1M-$4.8M
31 Mar 2025$168.9M$4.8M
31 Dec 2024$187.3M$16.0M
30 Sep 2024$168.6M-$143.5M
30 Jun 2024$178.0M$18.9M
31 Mar 2024$167.1M$9.0M
31 Dec 2023$181.2M$24.9M
30 Sep 2023$163.9M$10.9M
30 Jun 2023$169.5M$25.8M
31 Mar 2023$160.3M-$19.5M
31 Dec 2022$172.0M-$10.1M
30 Sep 2022$167.5M-$693K
30 Jun 2022$169.4M$19.9M
31 Mar 2022$158.0M$6.8M
31 Dec 2021–-$5.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $743.3M $716.8M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +3.7% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $37.7M $21.4M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $0.93 $0.46
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – 79.2% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 4.8% 5.8% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 5.1% 3.0% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 5.2% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $169.0M $124.2M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $295.6M $246.3M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $293.6M $376.7M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$2.0M (net cash) $130.4M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.41 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $17.77
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 38.8 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.0 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 2.0 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.1 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Pacira BioSciencesPCRX (this company) $1.5B38.82.0+3.7%5.1%
Damora TherapeuticsDMRA $1.4Bloss–––
Kailera TherapeuticsKLRA $1.4B––––
Sarepta TherapeuticsSRPT $1.4Bloss0.73-19%-5.9%
ADARx PharmaceuticalsADRX $1.4B––––
PrecigenPGEN $1.5B61.99.6–15.6%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-1.6%

$176.7M vs $179.5M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-6.3%

$3.6M vs $3.9M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$218K

bought $0, sold $218K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+3.2%

255 13F filers vs 247

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

45.7M shares held by 13F filers (30 Sep 2026) of 40.1M outstanding (4 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

8.4%

3.3M shares sold short (30 Oct 2026) of 40.1M outstanding (4 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.9

3.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-21%

4.3M shares sold short in the report before, 3.3M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

69%

69% of off-exchange volume on 16 Nov 2026 was short sales; 1-year average 58%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

22

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$90K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

41

41 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

41×

41 articles in the last 7 days; its usual week has 1.

Price $36.48 on 16 Nov 2026, +53% over 12 months (12-month range $19.16 to $36.49)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $2.4M in the last 12 months (the 12 months before: -$1.1M).
Revenue per quarter. Revenue $176.7M in the latest quarter, -1.6% on a year earlier.
Capital spending per quarter. Capital spending $3.6M in the latest quarter, -6.3% on a year earlier.
Institutional holders (13F filers). 255 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.
Lobbying spend. Lobbying spend: $90K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 16 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 20268-K and other filingsNine directors and six officers, including Frank D. Lee, ceased roles at Merger's Effective Time; Miraglia and Rainerman became Surviving Corporation officers
17 Nov 20268-K and other filingsNotified Nasdaq of Nov 17, 2026 merger closing; requested trading halt and delisting of shares via Form 25
17 Nov 20268-K and other filingsAcquired by Viatris via tender offer and merger, completed Nov 17, 2026, at $36.50 per Share in cash
17 Nov 20268-K and other filingsRepaid $96,392.50 and terminated Credit Agreement with Wells Fargo Bank, National Association, on Nov 17, 2026, in connection with the Merger
17 Nov 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Jun 20268-K and other filingsDirector or officer change
11 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Jan 20268-K and other filingsDirector or officer change
28 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Jul 20258-K and other filingsRestructuring costs announced
7 Jul 20258-K and other filingsA major agreement ended
13 Jun 20258-K and other filingsDirector or officer change
13 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 May 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 8.5M vs usual 3.1M (2025-03-31); 3.0x the same period a year earlier
30 Jan 20258-K and other filingsDirector or officer change
21 Jan 20258-K and other filingsDirector or officer change
6 Nov 20248-K and other filingsDirector or officer change
21 Oct 20248-K and other filingsDirector or officer change
27 Sep 20248-K and other filingsDirector or officer change
27 Sep 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Sep 2024Sharp changeShort interest spike: short interest spike, 6.0M vs usual 3.8M (2024-08-30); 1.7x the same period a year earlier
14 Aug 2024Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 157K)
13 Aug 2024Sharp changeShort interest spike: short interest spike, 6.3M vs usual 3.7M (2024-07-31); 1.8x the same period a year earlier
30 Jul 2024Sharp changeShort interest spike: short interest spike, 6.5M vs usual 3.7M (2024-07-15); 1.8x the same period a year earlier
16 Jul 2024Sharp changeShort interest spike: short interest spike, 6.7M vs usual 3.6M (2024-06-28); 1.9x the same period a year earlier
2 Jul 2024Sharp changeShort interest spike: short interest spike, 6.4M vs usual 3.6M (2024-06-14); 1.7x the same period a year earlier
18 Jun 2024Sharp changeShort interest spike: short interest spike, 6.4M vs usual 3.6M (2024-05-31); 1.8x the same period a year earlier
13 Jun 20248-K and other filingsDirector or officer change
13 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 May 2024Sharp changeShort interest spike: short interest spike, 6.0M vs usual 3.6M (2024-05-15); 1.8x the same period a year earlier
29 Feb 20248-K and other filingsDirector or officer change
21 Dec 20238-K and other filingsDirector or officer change
10 Oct 20238-K and other filingsDirector or officer change
26 Sep 20238-K and other filingsDirector or officer change
26 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jun 20238-K and other filingsDirector or officer change
20 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Apr 20238-K and other filingsA major agreement ended
22 Mar 20238-K and other filingsDirector or officer change
22 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Jun 20228-K and other filingsDirector or officer change
4 May 20228-K and other filingsDirector or officer change
4 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Jan 2022Sharp changeLobbying spend jump: lobbying spend jump, 180K vs usual 105K (2021-12-31); 2.0x the same period a year earlier
Insider net buying (open market)
Month from 1 Jan 2022: -$1.9M published
Month from 1 Feb 2022: -$117K published
Month from 1 Mar 2022: -$3.8M published
Month from 1 Apr 2022: -$4.5M published
Month from 1 May 2022: -$59K published
Month from 1 Jun 2022: -$4.7M published
Month from 1 Jul 2022: -$83K published
Month from 1 Aug 2022: -$44K published
Month from 1 Oct 2022: -$80K published
Month from 1 Jan 2023: -$27K published
Month from 1 Apr 2023: -$285K published
Month from 1 May 2023: -$502K published
Month from 1 Jun 2023: -$2.6M published
Month from 1 Jul 2023: -$25K published
Month from 1 Aug 2023: -$18K published
Month from 1 Mar 2024: -$3.7M published
Month from 1 Jun 2024: -$522K published
Month from 1 Jul 2024: -$80K published
Month from 1 Aug 2024: $197K published
Month from 1 Sep 2024: -$6K published
Month from 1 Dec 2024: -$10K published
Month from 1 Jan 2025: -$16K published
Month from 1 Jun 2025: -$523K published
Month from 1 Aug 2025: -$116K published
Month from 1 Sep 2025: -$64K published
Month from 1 Nov 2025: -$362K published
Month from 1 Dec 2025: -$627K published
Month from 1 Jan 2026: -$34K published
Month from 1 Feb 2026: -$353K published
Month from 1 Mar 2026: -$85K published
Month from 1 Apr 2026: -$628K published
Month from 1 Jun 2026: -$372K published
Month from 1 Aug 2026: -$71K published
Month from 1 Oct 2026: -$218K published
Revenue per quarter
Quarter ended 31 Mar 2022: $158.0M, +33% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $169.4M, +25% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $167.5M, +31% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $172.0M; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $160.3M, +1.5% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $169.5M, 0% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $163.9M, -2.1% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $181.2M, +5.4% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $167.1M, +4.2% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $178.0M, +5.0% on a year earlier; public on 31 Jul 2024
Quarter ended 30 Sep 2024: $168.6M, +2.8% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $187.3M, +3.3% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2025: $168.9M, +1.1% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $181.1M, +1.7% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $179.5M, +6.5% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $196.9M, +5.1% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $177.4M, +5.0% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $192.4M, +6.2% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $176.7M, -1.6% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $9.2M, -36% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $7.7M, -41% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $11.7M, +11% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $5.2M, -60% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $5.5M, -40% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $6.6M, -14% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $3.4M, -71% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $3.4M, -34% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $1.8M, -67% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $2.8M, -57% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $1.6M, -53% on a year earlier; public on 31 Jul 2024
Quarter ended 30 Sep 2024: $4.1M, +21% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $2.1M, +18% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $8.5M, +201% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $2.7M, +70% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $3.9M, -5.4% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $218K, -90% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $2.7M, -68% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $1.3M, -50% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $3.6M, -6.3% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 248; public on 14 Feb 2022
31 Mar 2022 report: 280; public on 16 May 2022
30 Jun 2022 report: 261; public on 15 Aug 2022
30 Sep 2022 report: 248; public on 14 Nov 2022
31 Dec 2022 report: 253; public on 14 Feb 2023
31 Mar 2023 report: 253; public on 15 May 2023
30 Jun 2023 report: 239; public on 14 Aug 2023
30 Sep 2023 report: 242; public on 14 Nov 2023
31 Dec 2023 report: 241; public on 14 Feb 2024
31 Mar 2024 report: 257; public on 15 May 2024
30 Jun 2024 report: 265; public on 14 Aug 2024
30 Sep 2024 report: 230; public on 14 Nov 2024
31 Dec 2024 report: 225; public on 14 Feb 2025
31 Mar 2025 report: 220; public on 15 May 2025
30 Jun 2025 report: 221; public on 14 Aug 2025
30 Sep 2025 report: 228; public on 14 Nov 2025
31 Dec 2025 report: 252; public on 17 Feb 2026
31 Mar 2026 report: 235; public on 15 May 2026
30 Jun 2026 report: 247; public on 14 Aug 2026
30 Sep 2026 report: 255; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $180K published
Quarter from 1 Apr 2022: $100K published
Quarter from 1 Jul 2022: $100K published
Quarter from 1 Oct 2022: $110K published
Quarter from 1 Jan 2023: $110K published
Quarter from 1 Oct 2026: $90K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is lobbying spend reported (quarter) at $90K (30 Sep 2026), 14% below its normal reading of $105K; higher than 25% of its own history.
  • Insider net buying (open market): Insiders sold a net $2.4M in the last 12 months (the 12 months before: -$1.1M).
  • Revenue per quarter: Revenue $176.7M in the latest quarter, -1.6% on a year earlier.
  • Capital spending per quarter: Capital spending $3.6M in the latest quarter, -6.3% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 1 sale, $218K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
9 Oct 2026Lauren RikerSenior Vice President, FinanceSellplanned in advance (10b5-1); after exercising options6,000$36.32$218KForm 4
18 Aug 2026Jonathan SloninChief Medical OfficerSellplanned in advance (10b5-1)3,040$23.23$71KForm 4
12 Jun 2026Lauren RikerSenior Vice President, FinanceSellplanned in advance (10b5-1)6,115$23.50$144KForm 4
5 Jun 2026Kristen WilliamsChief Administrative OfficerSellplanned in advance (10b5-1)10,259$22.27$228KForm 4
24 Apr 2026Shawn CrossChief Financial OfficerSellplanned in advance (10b5-1); after exercising options12,941$25.16$326KForm 4
22 Apr 2026Shawn CrossChief Financial OfficerSellplanned in advance (10b5-1); after exercising options12,059$25.09$303KForm 4
19 Mar 2026Jonathan SloninChief Medical OfficerSellplanned in advance (10b5-1)3,261$22.82$74KForm 4
19 Mar 2026Mark FroimsonDirectorSell500$21.81$11KForm 4

255 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 29 opened a position, 24 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Absolute Investment Advisers, LLC11.5M28.7%$11.3MNew+11.5M
BlackRock, Inc.6.9M17.3%$173.7M+230K+3.4%
Doma Perpetual Capital Management LLC2.8M6.93%$69.6MNo change
Vanguard Portfolio Management LLC2.4M5.92%$59.4M-34K-1.4%
Dimensional Fund Advisors LP2.3M5.67%$56.9M+168K+8.0%
State Street Corp2.1M5.35%$53.7M+85K+4.1%
D. E. Shaw & Co., Inc.1.9M4.67%$46.9M-78K-4.0%
Renaissance Technologies LLC1.7M4.17%$41.9M-62K-3.6%
Vanguard Capital Management LLC1.6M4.06%$40.7M-65K-3.8%
Goldman Sachs Group Inc1.5M3.70%$37.1M-44K-2.9%

Company events

All 61 company events

In 12 months: 3 director or officer changes, 3 major agreements, 1 agreement ended, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
17 Nov 2026Nine directors and six officers, including Frank D. Lee, ceased roles at Merger's Effective Time; Miraglia and Rainerman became Surviving Corporation officers; Entered supplemental indenture for $287.5M of 2.125% convertible notes due 2029, tied to merger; unwound capped call transactions; Repaid $96,392.50 and terminated Credit Agreement with Wells Fargo Bank, National Association, on Nov 17, 2026, in connection with the Merger; Acquired by Viatris via tender offer and merger, completed Nov 17, 2026, at $36.50 per Share in cash; Notified Nasdaq of Nov 17, 2026 merger closing; requested trading halt and delisting of shares via Form 25Same filing: a debt came due early, changed shareholder rights, change of control, changed its bylaws or fiscal year8-K
8 Oct 2026Signed a major agreement8-K
30 Jun 2026Signed a major agreement8-K
11 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
28 Jan 2026Director or officer change8-K
10 Jul 2025Restructuring costs announced8-K
7 Jul 2025Signed a major agreement; A major agreement endedSame filing: took on new debt8-K
13 Jun 2025Director or officer changeSame filing: shareholder vote results8-K

22 open postings; careers site tracked since 21 Nov 2026. Most in Sales & business development 50%, Operations & administration 14%, Data & analytics 9%, Legal, policy & compliance 5%.

PostedJobLocation
13 Nov 2026Director, CRM Strategy and OperationsOperations & administrationBrisbane, California
13 Nov 2026Associate Director, Incentive Compensation Analytics, Design and AdministrationPeople & recruitingBrisbane, California
11 Nov 2026Early Intervention Account Manager- Chicago, ILSales & business developmentIllinois, United States
10 Nov 2026Early Intervention Account Manager- Springfield, ILSales & business developmentUnited States
28 Oct 2026Executive Director, HEOR & ValueProgram & project managementUnited States
28 Oct 2026Regional Business Director - NortheastSales & business developmentNew York, United States
28 Oct 2026Metrology Specialist 2Process engineering (semiconductor / materials)San Diego, California
28 Oct 2026Regional Business Director- Pacific NorthwestSales & business developmentOregon, United States

Reported lobbying spend: $90K in Q3 2026, $110K in Q4 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Apr 2018NewVenn Strategiesfor Pacira Pharmaceuticals Inc.Improving access to non-opioid approaches to pain management.Health issuesFiling

The 5 newest of 191 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

14 Aug 2024confirmed

Confirmed across sources Insiders and Short interest and volume

Pacira BioSciences (PCRX): had 6.7M shares sold short in the 28 Jun 2024 report, 1.9× the same report last year, while it had 3 insiders buy $157K of its shares on the open market within 30 days (3 filings). Two unrelated kinds of activity within 28 days.

  • Short interest and volume: Short interest spike, became public on 11 Jul 2024
  • Short interest and volume: Short interest spike, became public on 25 Jul 2024
  • Short interest and volume: Short interest spike, became public on 10 Aug 2024
  • Insiders: Clustered insider buying, became public on 14 Aug 2024
2023-06-30: 3.6M2023-07-14: 3.5M2023-07-31: 3.4M2023-08-15: 3.7M2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M2024-05-31: 6.4M2024-06-14: 6.4M2024-06-28: 6.7M
The 28 Jun 2024 report against the 24 reports before it. this reportearliernormal: 3.6M
See the evidence (4 changes)

Short interest and volume: Short interest spike became public on 11 Jul 2024

Pacira BioSciences had 6.7M shares sold short in the 28 Jun 2024 report, 1.9× the same report last year.

This period
6.7M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
185K
How far from its usual level
+8.6
Same report last year
3.6M
History used
2,373 days
2023-06-30: 3.6M2023-07-14: 3.5M2023-07-31: 3.4M2023-08-15: 3.7M2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M2024-05-31: 6.4M2024-06-14: 6.4M2024-06-28: 6.7M
the 28 Jun 2024 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Jul 2024

Pacira BioSciences had 6.5M shares sold short in the 15 Jul 2024 report, 1.8× the same report last year.

This period
6.5M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
241K
How far from its usual level
+7.7
Same report last year
3.5M
History used
2,390 days
2023-07-14: 3.5M2023-07-31: 3.4M2023-08-15: 3.7M2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M2024-05-31: 6.4M2024-06-14: 6.4M2024-06-28: 6.7M2024-07-15: 6.5M
the 15 Jul 2024 report24 earlier reportsnormal: 3.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Aug 2024

Pacira BioSciences had 6.3M shares sold short in the 31 Jul 2024 report, 1.8× the same report last year.

This period
6.3M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
261K
How far from its usual level
+6.7
Same report last year
3.4M
History used
2,406 days
2023-07-31: 3.4M2023-08-15: 3.7M2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M2024-05-31: 6.4M2024-06-14: 6.4M2024-06-28: 6.7M2024-07-15: 6.5M2024-07-31: 6.3M
the 31 Jul 2024 report24 earlier reportsnormal: 3.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Insiders: Clustered insider buying became public on 14 Aug 2024

Pacira BioSciences had 3 insiders buy $157K of its shares on the open market within 30 days (3 filings).

Independent buyers
3
Purchase filings (Form 4, code P)
3
Total bought
$157K
Window
15 Jul 2024 to 14 Aug 2024

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

11 Aug 2020confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Pacira BioSciences (PCRX): had 8.1M shares sold short in the 15 Jul 2020 report, 2.3× the same report last year, while it spent $8.9M on capital projects in the quarter ended 30 Jun 2020, 4.3× the same quarter last year. Two unrelated kinds of activity within 21 days.

  • Short interest and volume: Short interest spike, became public on 25 Jul 2020
  • Financials: Quarterly capital spending jump, became public on 11 Aug 2020
  • Short interest and volume: Short interest spike, became public on 12 Aug 2020
2019-07-15: 3.5M2019-07-31: 3.3M2019-08-15: 3.3M2019-08-30: 2.7M2019-09-13: 2.9M2019-09-30: 3.5M2019-10-15: 4.4M2019-10-31: 4.5M2019-11-15: 4.4M2019-11-29: 3.9M2019-12-13: 3.7M2019-12-31: 3.8M2020-01-15: 4.2M2020-01-31: 4.5M2020-02-14: 4.4M2020-02-28: 4.4M2020-03-13: 4.3M2020-03-31: 4.0M2020-04-15: 4.6M2020-04-30: 5.2M2020-05-15: 5.3M2020-05-29: 5.3M2020-06-15: 5.5M2020-06-30: 6.5M2020-07-15: 8.1M
The 15 Jul 2020 report against the 24 reports before it. this reportearliernormal: 4.3M
See the evidence (3 changes)

Short interest and volume: Short interest spike became public on 25 Jul 2020

Pacira BioSciences had 8.1M shares sold short in the 15 Jul 2020 report, 2.3× the same report last year.

This period
8.1M (the 15 Jul 2020 report)
Normal report (median of 24 earlier)
4.3M
Typical spread (median absolute deviation)
604K
How far from its usual level
+4.1
Same report last year
3.5M
History used
929 days
2019-07-15: 3.5M2019-07-31: 3.3M2019-08-15: 3.3M2019-08-30: 2.7M2019-09-13: 2.9M2019-09-30: 3.5M2019-10-15: 4.4M2019-10-31: 4.5M2019-11-15: 4.4M2019-11-29: 3.9M2019-12-13: 3.7M2019-12-31: 3.8M2020-01-15: 4.2M2020-01-31: 4.5M2020-02-14: 4.4M2020-02-28: 4.4M2020-03-13: 4.3M2020-03-31: 4.0M2020-04-15: 4.6M2020-04-30: 5.2M2020-05-15: 5.3M2020-05-29: 5.3M2020-06-15: 5.5M2020-06-30: 6.5M2020-07-15: 8.1M
the 15 Jul 2020 report24 earlier reportsnormal: 4.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly capital spending jump became public on 11 Aug 2020

Pacira BioSciences spent $8.9M on capital projects in the quarter ended 30 Jun 2020, 4.3× the same quarter last year.

This period
$8.9M (the quarter ended 30 Jun 2020)
Normal quarter (median of 8 earlier)
$2.4M
Typical spread (median absolute deviation)
$634K
How far from its usual level
+6.5
Same quarter last year
$2.1M
History used
3,561 days
2018-06-30: $2.6M2018-09-30: $4.5M2018-12-31: $2.2M2019-03-31: $2.0M2019-06-30: $2.1M2019-09-30: $1.6M2019-12-31: $4.5M2020-03-31: $6.7M2020-06-30: $8.9M
the quarter ended 30 Jun 20208 earlier quartersnormal: $2.4M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 12 Aug 2020

Pacira BioSciences had 8.1M shares sold short in the 31 Jul 2020 report, 2.5× the same report last year.

This period
8.1M (the 31 Jul 2020 report)
Normal report (median of 24 earlier)
4.4M
Typical spread (median absolute deviation)
636K
How far from its usual level
+4.0
Same report last year
3.3M
History used
945 days
2019-07-31: 3.3M2019-08-15: 3.3M2019-08-30: 2.7M2019-09-13: 2.9M2019-09-30: 3.5M2019-10-15: 4.4M2019-10-31: 4.5M2019-11-15: 4.4M2019-11-29: 3.9M2019-12-13: 3.7M2019-12-31: 3.8M2020-01-15: 4.2M2020-01-31: 4.5M2020-02-14: 4.4M2020-02-28: 4.4M2020-03-13: 4.3M2020-03-31: 4.0M2020-04-15: 4.6M2020-04-30: 5.2M2020-05-15: 5.3M2020-05-29: 5.3M2020-06-15: 5.5M2020-06-30: 6.5M2020-07-15: 8.1M2020-07-31: 8.1M
the 31 Jul 2020 report24 earlier reportsnormal: 4.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 17 Nov 2026Filings change

    filed a director or officer change: Nine directors and six officers, including Frank D. Lee, ceased roles at Merger's Effective Time; Miraglia and Rainerman became Surviving Corporation officers.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 17 Nov 2026Filings record

    Nine directors and six officers, including Frank D. Lee, ceased roles at Merger's Effective Time; Miraglia and Rainerman became Surviving Corporation officers

  3. 17 Nov 2026Filings record

    Notified Nasdaq of Nov 17, 2026 merger closing; requested trading halt and delisting of shares via Form 25

  4. 17 Nov 2026Filings record

    Acquired by Viatris via tender offer and merger, completed Nov 17, 2026, at $36.50 per Share in cash

  5. 17 Nov 2026Filings record

    Repaid $96,392.50 and terminated Credit Agreement with Wells Fargo Bank, National Association, on Nov 17, 2026, in connection with the Merger

  6. 11 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 11 Jun 2026Filings record

    Director or officer change

  8. 28 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 28 Jan 2026Filings record

    Director or officer change

  10. 10 Jul 2025Filings record

    Restructuring costs announced

  11. 7 Jul 2025Filings record

    A major agreement ended

  12. 13 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 13 Jun 2025Filings record

    Director or officer change

  14. 13 May 2025Financials change

    spent $8.5M on capital projects in the quarter ended 31 Mar 2025, 3.0× the same quarter last year.

    Same quarter last year: $2.8M; its normal quarter is $3.1M.

    See the evidence
    This period
    $8.5M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $3.1M
    Typical spread (median absolute deviation)
    $987K
    How far from its usual level
    +3.7
    Same quarter last year
    $2.8M
    History used
    5,296 days
    2023-03-31: $6.6M2023-06-30: $3.4M2023-09-30: $3.4M2023-12-31: $1.8M2024-03-31: $2.8M2024-06-30: $1.6M2024-09-30: $4.1M2024-12-31: $2.1M2025-03-31: $8.5M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $3.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  15. 30 Jan 2025Filings record

    Director or officer change

  16. 21 Jan 2025Filings record

    Director or officer change

  17. 6 Nov 2024Filings record

    Director or officer change

  18. 21 Oct 2024Filings record

    Director or officer change

  19. 27 Sep 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 27 Sep 2024Filings record

    Director or officer change

  21. 12 Sep 2024Short interest and volume change

    had 6.0M shares sold short in the 30 Aug 2024 report, 1.7× the same report last year.

    Same report last year: 3.6M; its normal report is 3.8M.

    See the evidence
    This period
    6.0M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    3.8M
    Typical spread (median absolute deviation)
    340K
    How far from its usual level
    +4.4
    Same report last year
    3.6M
    History used
    2,436 days
    2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M2024-05-31: 6.4M2024-06-14: 6.4M2024-06-28: 6.7M2024-07-15: 6.5M2024-07-31: 6.3M2024-08-15: 5.2M2024-08-30: 6.0M
    the 30 Aug 2024 report24 earlier reportsnormal: 3.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 20 Aug 2024Insiders record

    BIGAL MARCELO (director) bought 1,512 shares of PCRX ($20,034) (dated 19 Aug 2024)

  23. 20 Aug 2024Insiders record

    Brege Laura (director) bought 1,000 shares of PCRX ($12,810) (dated 19 Aug 2024)

  24. 15 Aug 2024Insiders record

    YANG MICHAEL J. (director) bought 2,000 shares of PCRX ($25,800) (dated 14 Aug 2024)

  25. 14 Aug 2024several at once

    had 6.7M shares sold short in the 28 Jun 2024 report, 1.9× the same report last year, while it had 3 insiders buy $157K of its shares on the open market within 30 days (3 filings). Two unrelated kinds of activity within 28 days.

    See the evidence (4 changes)

    Short interest and volume: Short interest spike became public on 11 Jul 2024

    Pacira BioSciences had 6.7M shares sold short in the 28 Jun 2024 report, 1.9× the same report last year.

    This period
    6.7M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    185K
    How far from its usual level
    +8.6
    Same report last year
    3.6M
    History used
    2,373 days
    2023-06-30: 3.6M2023-07-14: 3.5M2023-07-31: 3.4M2023-08-15: 3.7M2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M2024-05-31: 6.4M2024-06-14: 6.4M2024-06-28: 6.7M
    the 28 Jun 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Jul 2024

    Pacira BioSciences had 6.5M shares sold short in the 15 Jul 2024 report, 1.8× the same report last year.

    This period
    6.5M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    241K
    How far from its usual level
    +7.7
    Same report last year
    3.5M
    History used
    2,390 days
    2023-07-14: 3.5M2023-07-31: 3.4M2023-08-15: 3.7M2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M2024-05-31: 6.4M2024-06-14: 6.4M2024-06-28: 6.7M2024-07-15: 6.5M
    the 15 Jul 2024 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Aug 2024

    Pacira BioSciences had 6.3M shares sold short in the 31 Jul 2024 report, 1.8× the same report last year.

    This period
    6.3M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    261K
    How far from its usual level
    +6.7
    Same report last year
    3.4M
    History used
    2,406 days
    2023-07-31: 3.4M2023-08-15: 3.7M2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M2024-05-31: 6.4M2024-06-14: 6.4M2024-06-28: 6.7M2024-07-15: 6.5M2024-07-31: 6.3M
    the 31 Jul 2024 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Insiders: Clustered insider buying became public on 14 Aug 2024

    Pacira BioSciences had 3 insiders buy $157K of its shares on the open market within 30 days (3 filings).

    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $157K
    Window
    15 Jul 2024 to 14 Aug 2024

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  26. 14 Aug 2024Insiders change

    had 3 insiders buy $157K of its shares on the open market within 30 days (3 filings).

    Who bought: Froimson Mark, Bigal Marcelo, Lee Frank D..

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $157K
    Window
    15 Jul 2024 to 14 Aug 2024

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  27. 14 Aug 2024Insiders record

    Lee Frank D. (Chief Executive Officer) bought 8,264 shares of PCRX ($99,994) (dated 13 Aug 2024)

  28. 14 Aug 2024Insiders record

    BIGAL MARCELO (director) bought 3,400 shares of PCRX [amended] [same transaction as an earlier filing] (dated 13 Aug 2024)

  29. 13 Aug 2024Insiders record

    BIGAL MARCELO (director) bought 3,400 shares of PCRX ($40,834) (dated 12 Aug 2024)

  30. 13 Aug 2024Insiders record

    Froimson Mark (director) bought 1,400 shares of PCRX ($16,212) (dated 12 Aug 2024)

  31. 10 Aug 2024Short interest and volume change

    had 6.3M shares sold short in the 31 Jul 2024 report, 1.8× the same report last year.

    Same report last year: 3.4M; its normal report is 3.7M.

    See the evidence
    This period
    6.3M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    261K
    How far from its usual level
    +6.7
    Same report last year
    3.4M
    History used
    2,406 days
    2023-07-31: 3.4M2023-08-15: 3.7M2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M2024-05-31: 6.4M2024-06-14: 6.4M2024-06-28: 6.7M2024-07-15: 6.5M2024-07-31: 6.3M
    the 31 Jul 2024 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 25 Jul 2024Short interest and volume change

    had 6.5M shares sold short in the 15 Jul 2024 report, 1.8× the same report last year.

    Same report last year: 3.5M; its normal report is 3.7M.

    See the evidence
    This period
    6.5M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    241K
    How far from its usual level
    +7.7
    Same report last year
    3.5M
    History used
    2,390 days
    2023-07-14: 3.5M2023-07-31: 3.4M2023-08-15: 3.7M2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M2024-05-31: 6.4M2024-06-14: 6.4M2024-06-28: 6.7M2024-07-15: 6.5M
    the 15 Jul 2024 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 11 Jul 2024Short interest and volume change

    had 6.7M shares sold short in the 28 Jun 2024 report, 1.9× the same report last year.

    Same report last year: 3.6M; its normal report is 3.6M.

    See the evidence
    This period
    6.7M (the 28 Jun 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    185K
    How far from its usual level
    +8.6
    Same report last year
    3.6M
    History used
    2,373 days
    2023-06-30: 3.6M2023-07-14: 3.5M2023-07-31: 3.4M2023-08-15: 3.7M2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M2024-05-31: 6.4M2024-06-14: 6.4M2024-06-28: 6.7M
    the 28 Jun 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 27 Jun 2024Short interest and volume change

    had 6.4M shares sold short in the 14 Jun 2024 report, 1.7× the same report last year.

    Same report last year: 3.6M; its normal report is 3.6M.

    See the evidence
    This period
    6.4M (the 14 Jun 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    151K
    How far from its usual level
    +7.6
    Same report last year
    3.6M
    History used
    2,359 days
    2023-06-15: 3.6M2023-06-30: 3.6M2023-07-14: 3.5M2023-07-31: 3.4M2023-08-15: 3.7M2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M2024-05-31: 6.4M2024-06-14: 6.4M
    the 14 Jun 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 13 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 13 Jun 2024Filings record

    Director or officer change

  37. 12 Jun 2024Short interest and volume change

    had 6.4M shares sold short in the 31 May 2024 report, 1.8× the same report last year.

    Same report last year: 3.5M; its normal report is 3.6M.

    See the evidence
    This period
    6.4M (the 31 May 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    145K
    How far from its usual level
    +7.9
    Same report last year
    3.5M
    History used
    2,345 days
    2023-05-31: 3.5M2023-06-15: 3.6M2023-06-30: 3.6M2023-07-14: 3.5M2023-07-31: 3.4M2023-08-15: 3.7M2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M2024-05-31: 6.4M
    the 31 May 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 25 May 2024Short interest and volume change

    had 6.0M shares sold short in the 15 May 2024 report, 1.8× the same report last year.

    Same report last year: 3.4M; its normal report is 3.6M.

    See the evidence
    This period
    6.0M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    152K
    How far from its usual level
    +6.9
    Same report last year
    3.4M
    History used
    2,329 days
    2023-05-15: 3.4M2023-05-31: 3.5M2023-06-15: 3.6M2023-06-30: 3.6M2023-07-14: 3.5M2023-07-31: 3.4M2023-08-15: 3.7M2023-08-31: 3.6M2023-09-15: 3.5M2023-09-29: 3.5M2023-10-13: 3.9M2023-10-31: 3.6M2023-11-15: 3.2M2023-11-30: 3.3M2023-12-15: 3.2M2023-12-29: 3.5M2024-01-12: 3.7M2024-01-31: 3.9M2024-02-15: 3.9M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 3.7M2024-04-15: 3.4M2024-04-30: 3.6M2024-05-15: 6.0M
    the 15 May 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 29 Feb 2024Filings record

    Director or officer change

  40. 21 Dec 2023Filings record

    Director or officer change

Showing the newest 40 of 101 entries; narrow the window or the kind of data to see older ones.

Not listed: 367 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001396814
Ticker
PCRX
Domain
pacira.com
Hq location
CA|BRISBANE|94005 (1 unverified)
Lobbying client
pacira pharmaceuticals
Name
Blue Acquisition Corp, Domestic Subsidiaries, International Subsidiaries, Pacira Belgium GmbH and 8 more
  • Federal lobbying disclosures (LDA)1 record, 60 data points1 Apr 2018 to 30 Sep 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)205 records7 Jan 2016 to 17 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1170 data points31 Dec 2008 to 4 Nov 2026
  • SEC Form 4 insider transactions226 records, 528 data points14 Jan 2016 to 9 Oct 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4170 data points1 Aug 2018 to 16 Nov 2026